In the United States, adrenal tumors are found incidentally in about 5% of the 80 million CT scans performed annually. Most of the tumors found will be benign, but a small fraction will be adrenal cortical carcinoma (ACC), a type of cancer with high mortality and frequent recurrence. With the devastating effects of ACC, early diagnosis of a malignant adrenal mass is imperative to ensure timely and appropriate therapy.
Mayo Clinic’s Clinical Mass Spectrometry Laboratory (CMSL) has added a new, noninvasive, and more accurate test to diagnose malignant adrenal tumors, via urinary steroid profiling. The test is the result of several years of analytical and clinical studies based on cutting-edge liquid chromatography, high-resolution, and accurate-mass mass spectrometry (HRAM LC-MS) measurement for 25 steroid metabolites in urine.
Irina Bancos, M.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.
Aids in assessing malignancy in adrenal masses
May aid in improving diagnostic and prognostic prediction and dissect disease mechanisms for the following applications:
This test is not useful for establishing eligibility for a specific treatment as results must be interpreted in conjunction with the clinical status of the patient.
Supplies: Urine Tubes, 5 mL (T465)
Container/Tube: Plastic urine tube
Specimen Volume: 4 mL
1. Collect urine for a full 24 hours (required) and record the total volume.
2. Do not add preservatives. Specimens containing preservatives will be canceled.
3. Entire 24 hour collection must be mixed well prior to aliquoting into a 5 mL plastic tube.
Day and Time Test Performed
Monday; 4 p.m.